Top Story

FDA grants orphan drug designation to sevuparin for sickle cell disease

March 26, 2015

The FDA granted orphan drug designation to sevuparin for the treatment of patients with sickle cell disease, according to a press release from the drug’s manufacturer.

Sevuparin (DF02, Dilaforette) is a proprietary polysaccharide drug which may restore blood flow and prevent further microvascular obstructions caused by abnormal blood cells in patients with sickle cell disease. The anti-adhesive properties of the agent could potentially treat underlying causes of vaso-occlusive crisis in patients with sickle cell disease, leading to earlier pain relief, shorter hospital stay, reduced need of opioids and improved quality of life, according to the release.

In the Journals

AF thromboembolic prophylaxis should focus on drug efficacy, not pharmacologic class

March 25, 2015
In patients with atrial fibrillation, researchers found no significant class effect for direct thrombin inhibitors or factor Xa inhibitors, according to meta-analysis…
Chris Bowden, MD FDA News

FDA grants orphan drug designation to AG-348 for pyruvate kinase deficiency

March 25, 2015
The FDA today granted orphan drug designation to AG-348 for the treatment of pyruvate kinase deficiency, a rare form of hemolytic anemia, according to a press release…
Margaret T. Lee, MD In the Journals

Vitamin D deficiency linked to acute pain in children with sickle cell disease

March 24, 2015
Vitamin D deficiency may be associated with vaso-occlusive complications in children with sickle cell disease, according to results of a cross-sectional study.Patients…
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Lowering Factor XI levels effective in prevention of venous thrombosis

Lowering Factor XI levels effective in prevention of venous thrombosis

December 11, 2014
SAN FRANCISCO – A late-breaking abstract presented at the ASH Annual Meeting and Exposition identified a novel…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
FDA News

FDA grants orphan drug designation to sevuparin for sickle cell disease

March 26, 2015
The FDA granted orphan drug designation to sevuparin for the treatment of patients with sickle cell disease, according to a press release from the…
In the Journals

AF thromboembolic prophylaxis should focus on drug efficacy, not pharmacologic class

March 25, 2015
In patients with atrial fibrillation, researchers found no significant class effect for direct thrombin inhibitors or factor Xa inhibitors, according…
Chris Bowden, MD FDA News

FDA grants orphan drug designation to AG-348 for pyruvate kinase deficiency

March 25, 2015
The FDA today granted orphan drug designation to AG-348 for the treatment of pyruvate kinase deficiency, a rare form of hemolytic anemia, according…
Margaret T. Lee, MD In the Journals

Vitamin D deficiency linked to acute pain in children with sickle cell disease

March 24, 2015
Vitamin D deficiency may be associated with vaso-occlusive complications in children with sickle cell disease, according to results of a…
In the Journals

Four-factor prothrombin complex concentrate shows promise for urgent vitamin K antagonist reversal

March 20, 2015
Treatment with four-factor prothrombin complex concentrate was superior to plasma for the urgent reversal of vitamin K antagonist-induced…
In the Journals

VTE risk higher for older women after autologous breast reconstruction

March 18, 2015
Age is not associated with risk for complications after implant-based breast reconstruction, but it does serve as an independent risk factor for…
In the Journals

Joint aspiration safe in children with acute hemarthrosis, severe hemophilia A

March 18, 2015
During an 11-year study period, boys in Western Australia with severe hemophilia A and acute hemarthrosis safely had joint aspiration to avoid joint…
In the Journals

Transfused fresh red cells fail to improve outcomes in critically ill adults

March 17, 2015
Critically ill adults who received a transfusion of fresh red cells demonstrated no significant improvement in 90-day mortality compared with those…
In the Journals

Direct oral anticoagulants appear safe for preventing cancer-related VTE

March 16, 2015
Direct oral anticoagulants may be as safe and effective as conventional anticoagulation for the prevention of venous thromboembolism in patients with…
In the Journals

Apixaban does not increase bleeding in patients with renal insufficiencies

March 12, 2015
Compared with conventional anticoagulants, use of apixaban resulted in a lower bleeding risk in patients with mild or moderate-to-severe renal…
More Headlines »
morganatic-roan
morganatic-roan